CL2007002672A1 - Compuesto de benceno marcado con fluor radiactivo; metodo para preparar dicho compuesto marcado; composicion que comprende dicho compuesto; metodo para diagnostico de enfermedades por imagenes; conjunto de elementos que comprende dicho compuesto; uso - Google Patents
Compuesto de benceno marcado con fluor radiactivo; metodo para preparar dicho compuesto marcado; composicion que comprende dicho compuesto; metodo para diagnostico de enfermedades por imagenes; conjunto de elementos que comprende dicho compuesto; usoInfo
- Publication number
- CL2007002672A1 CL2007002672A1 CL200702672A CL2007002672A CL2007002672A1 CL 2007002672 A1 CL2007002672 A1 CL 2007002672A1 CL 200702672 A CL200702672 A CL 200702672A CL 2007002672 A CL2007002672 A CL 2007002672A CL 2007002672 A1 CL2007002672 A1 CL 2007002672A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- marked
- illnesses
- fluor
- radioactive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Nuclear Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07090035A EP1964848A1 (en) | 2007-03-01 | 2007-03-01 | Radiofluorination methods |
EP07090079A EP1985624A3 (en) | 2007-04-23 | 2007-04-23 | Single step method of radiofluorination of biologically active compounds or biomolecules |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007002672A1 true CL2007002672A1 (es) | 2008-09-12 |
Family
ID=39522200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200702672A CL2007002672A1 (es) | 2007-03-01 | 2007-09-14 | Compuesto de benceno marcado con fluor radiactivo; metodo para preparar dicho compuesto marcado; composicion que comprende dicho compuesto; metodo para diagnostico de enfermedades por imagenes; conjunto de elementos que comprende dicho compuesto; uso |
Country Status (22)
Country | Link |
---|---|
US (1) | US20090317326A1 (es) |
EP (1) | EP2146753A2 (es) |
JP (1) | JP2010520229A (es) |
KR (1) | KR20090119966A (es) |
AR (1) | AR062796A1 (es) |
AU (1) | AU2007348145A1 (es) |
BR (1) | BRPI0721424A2 (es) |
CA (1) | CA2679514A1 (es) |
CL (1) | CL2007002672A1 (es) |
CO (1) | CO6220836A2 (es) |
CR (1) | CR11011A (es) |
DO (1) | DOP2009000210A (es) |
EA (1) | EA200901142A1 (es) |
EC (1) | ECSP099610A (es) |
IL (1) | IL200034A0 (es) |
MX (1) | MX2009009291A (es) |
PA (1) | PA8747701A1 (es) |
PE (1) | PE20081355A1 (es) |
SV (1) | SV2009003364A (es) |
TW (1) | TW200836764A (es) |
UY (1) | UY30595A1 (es) |
WO (1) | WO2008104203A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
CN104974024B (zh) | 2008-03-21 | 2017-11-14 | 综合医院公司 | 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物 |
US20100129290A1 (en) * | 2008-11-26 | 2010-05-27 | I.S.T. Corporation | Smart contrast agent and detection method for detecting transition metal ions |
US20100227794A1 (en) * | 2008-11-26 | 2010-09-09 | I.S.T. Corporation | Smart contrast agent and method for detecting transition metal ions and treating related disorders |
GB201013808D0 (en) * | 2010-08-18 | 2010-09-29 | Ge Healthcare Ltd | Peptide radiotracer compositions |
KR101478140B1 (ko) * | 2011-05-13 | 2014-12-31 | (주)퓨쳐켐 | 18f-표지 pet 방사성의약품의 전구체 및 그 제조방법 |
CA2838198A1 (en) * | 2011-06-09 | 2012-12-13 | Ge Healthcare Limited | Distillation device and method |
EP2540710A1 (en) | 2011-06-30 | 2013-01-02 | Bayer Schering Pharma Aktiengesellschaft | New precursors for direct radiosynthesis of protected derivatives of O-([18F]Fluoromethyl) tyrosine |
RU2014102887A (ru) | 2011-06-30 | 2015-08-10 | Пирамаль Имэджинг Са | Прямой синтез 18f-фторметокси соединений для пэт визуализации и новые предшественники для прямого радиосинтеза защищенных производных o-([18f]фторметил)тирозина |
GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723578A (en) * | 1987-09-24 | 1998-03-03 | The Administrators Of Tulane Educational Fund | Peptide analogs of bombesin |
US5084555A (en) * | 1989-08-21 | 1992-01-28 | The Administrators Of The Tulane Educational Fund | An octapeptide bombesin analog |
US6083915A (en) * | 1991-05-10 | 2000-07-04 | Biomeasure, Inc. | Method for treating liver cancer |
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
US6639076B1 (en) * | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
EP1192132B1 (en) * | 1999-06-14 | 2005-09-07 | Eli Lilly And Company | Serine protease inhibitors |
EP1347784A2 (en) * | 2000-11-03 | 2003-10-01 | Bristol-Myers Squibb Pharma Company | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation |
WO2002044144A2 (en) * | 2000-11-30 | 2002-06-06 | Advanced Research And Technology Institute, Inc. | Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds |
TWI311133B (en) * | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
CA2516685A1 (en) * | 2003-02-20 | 2004-09-02 | University Of South Florida | Peptidomimetic inhibitors of stat3 activity and their medical uses |
GB0305704D0 (en) * | 2003-03-13 | 2003-04-16 | Amersham Plc | Radiofluorination methods |
WO2005002293A2 (en) * | 2003-06-25 | 2005-01-06 | Vanderbilt University | Cox-2-targeted imaging agents |
GB0420344D0 (en) * | 2004-09-14 | 2004-10-13 | Amersham Plc | Diagnostic compounds |
JP2008515875A (ja) * | 2004-10-07 | 2008-05-15 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 医療のイメージングに用いる化合物、キット及び方法 |
WO2006083424A2 (en) * | 2004-12-28 | 2006-08-10 | The Trustees Of Columbia University In The City Of New York | Radiolabeled compounds and uses thereof |
CA2594770C (en) * | 2005-01-17 | 2013-10-15 | Universitatsklinikum Munster | 5-pyrrolidinylsulfonyl isatin derivatives |
EP2063918B1 (en) * | 2006-09-08 | 2014-02-26 | Piramal Imaging SA | Compounds and methods for 18f labeled agents |
-
2007
- 2007-09-07 AU AU2007348145A patent/AU2007348145A1/en not_active Abandoned
- 2007-09-07 BR BRPI0721424-3A patent/BRPI0721424A2/pt not_active IP Right Cessation
- 2007-09-07 EP EP07802293A patent/EP2146753A2/en not_active Withdrawn
- 2007-09-07 WO PCT/EP2007/007967 patent/WO2008104203A2/en active Application Filing
- 2007-09-07 JP JP2009551918A patent/JP2010520229A/ja active Pending
- 2007-09-07 CA CA002679514A patent/CA2679514A1/en not_active Abandoned
- 2007-09-07 KR KR1020097018125A patent/KR20090119966A/ko not_active Application Discontinuation
- 2007-09-07 MX MX2009009291A patent/MX2009009291A/es not_active Application Discontinuation
- 2007-09-07 EA EA200901142A patent/EA200901142A1/ru unknown
- 2007-09-07 US US11/851,940 patent/US20090317326A1/en not_active Abandoned
- 2007-09-10 TW TW096133847A patent/TW200836764A/zh unknown
- 2007-09-14 PE PE2007001248A patent/PE20081355A1/es not_active Application Discontinuation
- 2007-09-14 PA PA20078747701A patent/PA8747701A1/es unknown
- 2007-09-14 UY UY30595A patent/UY30595A1/es not_active Application Discontinuation
- 2007-09-14 CL CL200702672A patent/CL2007002672A1/es unknown
- 2007-09-14 AR ARP070104088A patent/AR062796A1/es unknown
-
2009
- 2009-07-23 IL IL200034A patent/IL200034A0/en unknown
- 2009-09-01 EC EC2009009610A patent/ECSP099610A/es unknown
- 2009-09-01 SV SV2009003364A patent/SV2009003364A/es not_active Application Discontinuation
- 2009-09-01 DO DO2009000210A patent/DOP2009000210A/es unknown
- 2009-09-01 CR CR11011A patent/CR11011A/es unknown
- 2009-09-01 CO CO09092675A patent/CO6220836A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20081355A1 (es) | 2008-12-05 |
US20090317326A1 (en) | 2009-12-24 |
KR20090119966A (ko) | 2009-11-23 |
BRPI0721424A2 (pt) | 2014-03-25 |
TW200836764A (en) | 2008-09-16 |
CO6220836A2 (es) | 2010-11-19 |
AU2007348145A1 (en) | 2008-09-04 |
MX2009009291A (es) | 2009-12-14 |
DOP2009000210A (es) | 2010-08-31 |
ECSP099610A (es) | 2009-10-30 |
AR062796A1 (es) | 2008-12-03 |
EP2146753A2 (en) | 2010-01-27 |
CA2679514A1 (en) | 2008-09-04 |
WO2008104203A2 (en) | 2008-09-04 |
JP2010520229A (ja) | 2010-06-10 |
SV2009003364A (es) | 2010-01-27 |
UY30595A1 (es) | 2008-09-30 |
IL200034A0 (en) | 2010-04-15 |
EA200901142A1 (ru) | 2010-04-30 |
CR11011A (es) | 2009-10-19 |
PA8747701A1 (es) | 2009-08-26 |
WO2008104203A3 (en) | 2009-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007002672A1 (es) | Compuesto de benceno marcado con fluor radiactivo; metodo para preparar dicho compuesto marcado; composicion que comprende dicho compuesto; metodo para diagnostico de enfermedades por imagenes; conjunto de elementos que comprende dicho compuesto; uso | |
CL2007002620A1 (es) | Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto. | |
UY31806A (es) | Compuestos de tiazole y oxazole de sulfonamida de benceno | |
BR112012027147A2 (pt) | método in vitro destinado à liberação de um composto de vitamina d e à medição de um composto de vitamina d, composição e mistura de reagente, uso de uma composição de reagente e kits | |
BRPI0809977A2 (pt) | Uso de um composto, compostos e composição farmacêutica que o contém | |
CL2007001759A1 (es) | Compuesto metformina r-(+) lipoato; mezcla que comprende metformina y acido r-(+) lipoico; composicion farmaceutica que comprende el compuesto; metodo para preparar el compuesto; kit; y uso para tratar la diabetes. | |
CL2008000094A1 (es) | Compuestos derivados de pteridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para aumentar la vasodilatacion. | |
BRPI0821496A2 (pt) | Composições nanopartículas que proporcionam aprimorada coloração para formulações cosméticas | |
CL2008000703A1 (es) | Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos. | |
BR112014007134A2 (pt) | usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto | |
BRPI0814975A2 (pt) | Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltipla | |
CL2008000887A1 (es) | Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de | |
CL2008000794A1 (es) | Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro. | |
BRPI0906475A2 (pt) | Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto | |
BRPI0814811A2 (pt) | Composto, agente, método, e composição de diagnóstico, uso de um composto, e, método de formação de imagem | |
CL2007002021A1 (es) | Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias. | |
BR112013028959A2 (pt) | composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
CL2007002989A1 (es) | Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3. | |
CL2008002726A1 (es) | Compuestos derivados de isoquinolinilo e isoindolinilo, antagonistas de histamina-3; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos del sistema nervioso c | |
BR112012004173A2 (pt) | "composto, composição, método para preparar uma composição, e, uso de um composto" | |
BRPI0810399A2 (pt) | Composto, composição farmacêutica que o contém e uso do mesmo | |
CL2007003041A1 (es) | Compuesto inhibidor de proteina quinasa activada por mitogeno; proceso para obtener dicho compuesto; compuesto intermediario; composicion farmaceutica que comprende dicho compuesto inhibidor; kit que comprende dicho compuesto; y uso de un compuesto p | |
CL2008000463A1 (es) | Compuestos derivados de benzofuranos sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar infecciones parasitarias. | |
CO6980142A1 (es) | Composición de catalizador que se propone para el uso con composiciones puzolánicas | |
UY30596A1 (es) | Marcacion con fluor radioactivo |